We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ramcon A/S (Denmark) Distributes and Supports Anagnostics Products
News

Ramcon A/S (Denmark) Distributes and Supports Anagnostics Products

Ramcon A/S (Denmark) Distributes and Supports Anagnostics Products
News

Ramcon A/S (Denmark) Distributes and Supports Anagnostics Products

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ramcon A/S (Denmark) Distributes and Supports Anagnostics Products"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Since February of this year Danish Ramcon A/S offers Anagnostics’ drugs of abuse testing and pharmacogenetics solutions as distribution partner.

During the course of the year, further products, especially relating to severe infection testing will follow.

Establishing the innovative products in the Northern European Countries as well as competent and first class customer support are common goals of the partners.

“The decision to partner with Ramcon simply made sense, since Ramcon already specializes in tests and systems for in vitro diagnostics and life sciences with a loyal and broad customer base. Ramcon focuses on first class end-user service and support. Therefore both organizations perfectly fit together”, summarizes Markus Jaquemar, CMO Anagnostics Bioanalysis GmbH.

Jesper Hardt, CEO of Ramcon A/S, is looking forward to a successful partnership: “We can see a clear trend towards multiplex testing. Anagnostics perfectly responds to these market needs with the hyborg system and its testing menu. The fast and efficient response to actual drug consumption will secure access to drug therapy institutions. The efficient and highly sensitive pharmacogenetics test will benefit small or mid-sized pathological entities.”

Multiplex Diagnostics with Focus on Drugs of Abuse Screening, Pharmacogenetics (Oncology) and Serve Infection Testing Anagnostics Bioanalysis with its headquarters in St. Valentin (Austria) is specialized in developing systems, devices and tests in drugs of abuse screening, pharmacogenetics (oncology) and tests for diagnosing severe infections.

With the unique ability to perform protein as well as DNA based assays the hyborg system offers a testing platform meeting needs of personalized medicine and integrated diagnostics.

Anagnostics was established in 2005 by Bernhard Ronacher, a molecular genetics scientist. A cylindrical microarray - the hybcell - is the core of the patented multiplex technology.

Combined with the hyborg analysis system multi-parameter assays are performed in a fully automated manner.

Advertisement